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nDITORIAL COMMENT
nterleukin-10: Biomarker
r Pathologic Cytokine
n Fulminant Myocarditis?*
irk U. Knowlton, MD, FACC,
oshitaka Yajima, MD, PHD
a Jolla, California
“. . . science, I am told, may go astray: the doctors [are] not
able to discriminate between the counterfeit and the real.”
Fyodor Dostoevsky, The Brothers Karamozov, 1879
Sensitive and specific serologic markers for myocardial
nfarction (MI) and heart failure (HF) are now being
ncorporated into routine clinical practice with a great
nfluence on physicians’ decision making. To have such
erologic markers for myocarditis is a worthy goal because
he diagnosis depends on a non-specific clinical history and
ndings, exclusion of other cardiovascular diseases, and/or
ndomyocardial biopsy, a highly invasive procedure that has
oor sensitivity (1–3). Indeed, discrimination between pa-
ients with a favorable prognosis and those without is
urrently more in the realm of art than science.
See page 1292
In this issue of the Journal, Nishii et al. (4) addressed a
hallenging question: “are there serologic biomarkers that
ill predict the prognosis of patients with fulminant myo-
arditis?” This is a particularly important question because it
as been demonstrated that despite the severity of disease at
resentation, a high percentage of patients will survive and
ompletely recover once they overcome the acute phase (5).
iven the effectiveness of cardiac assist devices in patients
alling into the category of severe HF who are being treated
ith high doses of catecholamines, it would be valuable to
ave serologic markers that would identify those patients
ho are most likely to need mechanical support and those
ho are not. To address these questions, the authors studied
2 consecutive patients that fit the definition of fulminant
yocarditis: a distinct onset of HF after flu-like symptoms
equiring high-dose catecholamines with histologically
roven myocarditis (5,6). The patients were then classified
nto three groups: group 1—patients who had already lapsed
nto cardiogenic shock requiring mechanical cardio-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.sFrom the University of California, San Diego, La Jolla, California.ulmonary support on admission; group 2—patients who
nexpectedly lapsed into cardiogenic shock requiring me-
hanical cardiopulmonary support more than two days after
igh-dose catecholamine treatment had started; and group
—patients who required only high-dose catecholamines
ithout mechanical cardiopulmonary support.
Of the alterations that were observed in serum cytokines
nd C-reactive protein (CRP), the most striking finding was
hat the admission serum interleukin (IL)-10 level discimi-
ated patients who would require mechanical cardiopulmo-
ary assistance after admission to be discriminated from
hose who would not require such assistance. In addition,
hose who would ultimately die from their disease had the
ighest levels of IL-10. Importantly, average serum IL-10
evels were higher in patients with fulminant myocarditis
han in patients with acute MI who also required mechan-
cal cardiopulmonary support, and none of the patients with
ither fatal or non-fatal MI requiring mechanical support
ad IL-10 levels as high as those that died of fulminant
yocarditis. These findings indicate that IL-10 might be a
seful prognostic marker in patients with fulminant myo-
arditis, whereas other inflammatory markers such as tumor
ecrosis factor alpha and serum CRP were not as predictive
or mortality and the need for mechanical support in this
tudy. In addition, these data demonstrate that inflamma-
ory markers such as IL-10, tumor necrosis factor alpha, and
RP are higher in patients with fulminant myocarditis than
n severely ill patients with acute MI. Although this is not
articularly surprising, given the inflammatory nature of
yocarditis, it sheds a ray of hope that there may be a profile
f serologic biomarkers that will discriminate myocarditic
rom non-inflammatory causes of cardiac dysfunction. Their
ndings provide meaningful prognostic and diagnostic in-
ormation that could be useful in the management of
atients with fulminant myocarditis.
ROGNOSIS OF FULMINANT VERSUS
CUTE NON-FULMINANT MYOCARDITIS
f we focus on acute myocarditis only, a somewhat paradox-
cal observation has been reported: patients with fulminant
yocarditis have an excellent long-term prognosis despite
ery severe hemodynamic compromise upon presentation. A
linicopathologic classification using both histologic and
linical features has been published that provides prognostic
nformation in patients with acute myocarditis (6). Based on
his classification, a prospective study was performed that
emonstrated that 93% of patients with fulminant myocar-
itis were alive without heart transplantation 11 years after
iagnosis, compared with only 45% of those with acute
on-fulminant myocarditis (5). These observations strongly
upport aggressive therapy, including mechanical cardiac
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September 15, 2004:1298–300 Editorial Commentupport, when necessary, in patients with fulminant myo-
arditis (7–10).
OTENTIAL IMPACT OF SERUM IL-10
EVELS ON CLINICAL MANAGEMENT
he cause of myocarditis in a given patient has been very
ifficult to define; however, pertaining to fulminant myo-
arditis, the article by Nishii et al. (4) suggests that IL-10
evels could facilitate the management of patients with
ulminant myocarditis by predicting those that are likely to
evelop severe hemodynamic compromise requiring a ven-
ricular assist device. Although the data do not address
hether early implantation of a cardiac assist device would
e beneficial in patients with high levels of IL-10, they do
uggest that more intense monitoring and management
ould be appropriate in these patients. For example, in the
etting of high IL-10 levels, surgeons could be notified of
he patient’s status, and preparations for potential implan-
ation of a ventricular assist device could be undertaken.
lternatively, in the setting of lower IL-10 levels, a less
ggressive management strategy may be appropriate.
PATHOGENIC ROLE FOR IL-10 IN MYOCARDITIS?
he data presented in the study by Nishii et al. (4)
emonstrate that IL-10 might be used as a prognostic
iomarker in myocarditis; however, the strong association
etween IL-10 and prognosis raises the question of whether
L-10 levels may have a pathogenic role in the course of
yocarditis as well. It is known that both direct viral injury
nd the immune response of the host can have important
oles in myocarditis (11). Results from experiments in murine
odels of myocarditis indicate that although the immune
esponse has an important protective role, it also may have
eleterious effects on the host. The balance between these
rotective and deleterious effects may ultimately determine the
ourse of disease after enteroviral infection.
Interleukin-10 generally is thought of as an immunosup-
ressive cytokine (12), but its exact role in myocarditis is not
lear. It has been demonstrated that IL-10 has a protective
ole in experimental autoimmune myocarditis (13). Alter-
atively, it is conceivable that induction of an IL-10
mmunosuppressive effect could decrease the host defense
gainst viral infection and thus be detrimental to the host.
n example of where this appears to be true is in relation to
he Epstein-Barr virus, which has incorporated a copy of
L-10 known as viral interleukin (vIL)-10 into its genome
14). Because Epstein-Barr has evolved with vIL-10 in the
enome, it is likely that it is beneficial to viral replication.
Although the data presented by Nishii et al. (4) do not
efine a pathologic role for IL-10 in myocarditis, the data
o suggest the testable hypothesis that high levels of IL-10
ould have a role in the pathogenesis of the disease: aechanism that could have implications on its diagnosis
nd treatment.
UTURE DIRECTIONS
n the basis of this initial result, consideration should be
iven to a multi-center study employing a larger population
o confirm the significance of serum IL-10 levels in patients
ith both fulminant and non-fulminant myocarditis, in-
luding chronic active or persistent myocarditis. Given the
ifficulty of diagnosis of myocarditis, it would be valuable if
“footprint” of myocarditis could be defined using serum
arkers in place of myocardial biopsy. Ideally, this should
nclude prognostic and etiologic markers of the disease.
lthough these goals may seem to be out of reach, it was not
ong ago that the best biomarker for MI was measurement
f lactate dehydrogenase and serum glutamic oxaloacetic
ransaminase, enzymes that are expressed at high levels in
he liver. Now, serum levels of highly specific and sensitive
arkers of MI are available that provide valuable prognostic
nformation. We can only anticipate that consistent steady
rogression of knowledge from bench to bedside will
acilitate diagnostic and prognostic breakthroughs in this
eemingly invincible disease, thus providing a scientific tool
hat will discriminate between real myocarditis and its
ounterfeits.
eprint requests and correspondence: Dr. Kirk U. Knowlton,
niversity of California, San Diego, 9500 Gilman Drive, 0613K,
a Jolla, California 92093-0613. E-mail: kknowlton@ucsd.edu.
EFERENCES
1. Mason JW, O’Connell JB, Herskowitz A, et al. A clinical trial of
immunosuppressive therapy for myocarditis. The Myocarditis Treat-
ment Trial Investigators. N Engl J Med 1995;333:269–75.
2. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right
ventricular endomyocardial biopsy in the diagnosis of myocarditis.
J Am Coll Cardiol 1989;14:915–20.
3. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem
endomyocardial biopsy specimens from 38 patients with lymphocytic
myocarditis: implications for role of sampling error. Mayo Clin Proc
1989;64:1235–45.
4. Nishii M, Inomata T, Takehana H, et al. Serum levels of
interleukin-10 on admission as a prognostic predictor of human
fulminant myocarditis. J Am Coll Cardiol 2004;44:1292–7.
5. McCarthy RE, 3rd, Boehmer JP, Hruban RH, et al. Long-term
outcome of fulminant myocarditis as compared with acute (nonfulmi-
nant) myocarditis. N Engl J Med 2000;342:690–5.
6. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman
KL. Clinicopathologic description of myocarditis. J Am Coll Cardiol
1991;18:1617–26.
7. Rockman HA, Adamson RM, Dembitsky WP, Bonar JW, Jaski BE.
Acute fulminant myocarditis: long-term follow-up after circulatory
support with left ventricular assist device. Am Heart J 1991;121:
922–6.
8. Chang AC, Hanley FL, Weindling SN, Wernovsky G, Wessel DL.
Left heart support with a ventricular assist device in an infant with
acute myocarditis. Crit Care Med 1992;20:712–5.9. Jett GK, Miller A, Savino D, Gonwa T. Reversal of acute fulminant
11
1
1
1
1300 Knowlton and Yajima JACC Vol. 44, No. 6, 2004
Editorial Comment September 15, 2004:1298–300lymphocytic myocarditis with combined technology of OKT3
monoclonal antibody and mechanical circulatory support. J Heart
Lung Transplant 1992;11:733–8.
0. Yasu T, Murata S, Katsuki T, et al. Acutely severe myocarditis
successfully treated by percutaneous cardiopulmonary support applied
by a newly developed heparin-binding oxygenator and circuits. Jpn
Circ J 1997;61:1037–42.
1. Knowlton KU, Badorff C. The immune system in viral myocarditis:
maintaining the balance. Circ Res 1999;85:559–61.2. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multi-faceted relationship between IL-10 and adaptive immunity: putting
together the pieces of a puzzle. Cytokine Growth Factor Rev 2004;
15:61–76.
3. Watanabe K, Nakazawa M, Fuse K, et al. Protection against autoim-
mune myocarditis by gene transfer of interleukin-10 by electropora-
tion. Circulation 2001;104:1098–100.
4. Salek-Ardakani S, Arrand JR, Mackett M. Epstein-Barr virus encoded
interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on
human monocytes: implications for immune evasion by EBV. Virology
2002;304:342–51.
